Anovel paclitaxel loaded noisome: preparation, characterization and cytotoxicity assessment against human prostate cancer

Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 477

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NASTARANCANSER03_039

تاریخ نمایه سازی: 7 اسفند 1396

Abstract:

Regarding that prostate cancer is the most common form of cancer in men and is the second leading cause of cancer mortality, Paclitaxel, as a chemotherapeutic agent with a wide spectrum of antitumoractivity, could be utilized in treatment of this malignancy. Paclitaxel side effects are severe hypersensitivity reactions, neurotoxicity, and nephrotoxicity. Today’s decline of side effects and increase in efficacy of chemotherapeutic agents by applying nanotechnology in medicine is the target of scientists. iosomes or non-ionic surfactant vesicles are of paramount importance as delivery systems. Our present work investigated the efficiency of encapsulation of Paclitaxel in niosome as a novel vesicular drug delivery system and cytotoxic effects on prostate cancer cell line. In this experimental study, Paclitaxel-loaded niosome was prepared by the thin film hydration method. Dynamic light scattering and UV-V spectrophotometry were applied to evaluate the quality of the nanoniosomes including encapsulation efficiency, particle size, polydispersity index and zeta- potential measurements. Finally, MTT assay were utilized to specify anticancer activity of nanocarriers to PC3 human Paclitaxel in the niosomal formulation was encapsulated with a high entrapment efficiency of 99.4%. The polydispersity index, average diameter and zeta potentials of niosome prepared were determined to be 0.203, 119.7 nm and -4, respectively. The Paclitaxel optimized formula displayed significantly greater cytotoxic activity with PC3 prostate cancer cell line in comparison free Paclitaxel. Our results attained successful formulation of Paclitaxel niosomal thus demonstrating that nanoparticle-based formulation of Paclitaxel has high potential as an adjuvant therapy for clinical usage in prostate cancer

Keywords:

Prostate Cancer , Cancer Diagnosis , Cancer Treatment and Management , Drugs and Cancer , Chemotherapy

Authors

Ashraf Alemi

Department Of Clinical Biochemistry, Faculty Of Medicine, Shahid Sadoughi University Of Medical Sciences, Yazd, Iran)

Javad Zavvar Reza

Department Of Clinical Biochemistry, Faculty Of Medicine, Shahid Sadoughi University Of Medical Sciences, Yazd, Iran

Mohammad Farrokhifar

Kar Higher Education Institute Of Rafsanjan, Rafsanjan, Iran

Zakieh Entezari Nasab

Department Of Pediatrics, Semnan University Of Medical Sciences, Semnan, Iran